Hepatitis C

Latest News

Cost-effectiveness of Total State Coverage for Hepatitis C Medications

By William V. Padula, PhD
Jonathan S. Levin, PhD

May 20th 2021

Expanded coverage under a Medicare-Medicaid partnership to treat all prevalent cases of hepatitis C appears to be cost-effective by saving money and improving patient outcomes.

Nobel Prize

Discovery of Hepatitis C Virus Brings Nobel Prize

By Mary Caffrey

October 5th 2020

HIV, Hepatitis C Testing Rates Remain Dismal Among Injection Drug Users

HIV, Hepatitis C Testing Rates Remain Dismal Among Injection Drug Users

By Maggie L. Shaw

April 17th 2020

Updated Hepatitis C Screening Recommendations Expand to Cover Adolescents, DAAs

Updated Hepatitis C Screening Recommendations Expand to Cover Adolescents, DAAs

By Maggie L. Shaw

March 2nd 2020

From the Editorial Board: Jeffrey D. Dunn, PharmD, MBA

By Jeffrey D. Dunn, PharmD, MBA

February 15th 2020

More News

Louisiana Gets Creative to Improve Patient Access to Costly Hepatitis C Treatment

July 19th 2018

Louisiana Gets Creative to Improve Patient Access to Costly Hepatitis C Treatment

Surabhi Dangi-Garimella, PhD

Rebekah Gee, MD, Louisiana’s secretary of the Department of Health, is working on innovative solutions to ensure patient access to costly drugs within existing financial resources.

What We're Reading: Gawande's Challenges; US Opposed Breast Milk Resolution; Prisoners With HCV Not Treated

July 9th 2018

What We're Reading: Gawande's Challenges; US Opposed Breast Milk Resolution; Prisoners With HCV Not Treated

Atul Gawande, MD, starts his new job today leading the healthcare venture started by Amazon, JPMorgan Chase, and Berkshire Hathaway; what should have been an easy resolution at the United Nations–affiliated World Health Assembly this spring became ensnared in a US-led battle against breast milk; the majority of prison inmates with hepatitis C are not getting potentially curable drug treatment.

May 9th 2018

Monitoring the Hepatitis C Care Cascade Using Administrative Claims Data

Cheryl Isenhour, DVM, MPH Susan Hariri, PhD Claudia Vellozzi, MD, MPH

Development, validation, and application of hepatitis C case-finding algorithms to describe the care cascade among a commercially insured population in the United States.

May 3rd 2018

Increasing Hepatitis C Screening in a Large Integrated Health System: Science and Policy in Concert

Carla V. Rodriguez, PhD Kevin B. Rubenstein, MS Benjamin Linas, MD Haihong Hu, MS Michael Horberg, MD

The success of recommendations to improve screening often rests on the availability of efficacious therapies, coverage policies, and other factors that enable and justify screening.

September 12th 2017

What We're Reading: J&J Ends HCV Development; Suicides in Drug Trials; Off-Label Prescribing

August 4th 2017

What We're Reading: Senate Passes FDA Funding; Florida Medicaid Demonstration; New HCV Drug

Alison Rodriguez

July 19th 2017

FDA Approves HCV Treatment Vosevi for Previously Treated Patients

Alison Rodriguez

The FDA recently approved Vosevi-a fixed-dose combination tablet containing FDA-approved sofosbuvir and velpatasvir, and a new drug, voxilaprevi-to treat adults with the hepatitis C virus who do not have cirrhosis (liver disease).

May 19th 2017

5 Priorities During National Women's Health Week

Christina Mattina

Every year, the week beginning with Mother’s Day is designated as National Women’s Health Week, meant to shine a spotlight on the unique health challenges affecting women in America.

May 18th 2017

What We're Reading: Amazon Pharmacy Speculation; Successful High-Risk Pools; Penn. Expands HCV Treatment

April 20th 2017

The Oncogenic Hepatitis C Virus and Direct-Acting Antivirals: Economic Implications for Hepatocellular Carcinoma in Medicaid Beneficiaries With Cirrhosis

S. Mantravadi, PhD, MS, MPH

The oncogenic effects of the hepatitis C virus can impact patient outcomes for hepatocellular carcinoma (HCC) and have economic implications for medical spending. This study underscores the importance of treating patients early in the disease process for savings associated with reducing the risks of HCC.

February 16th 2017

Treating Medicaid Patients With Hepatitis C: Clinical and Economic Impact

Zobair Younossi, MD Stuart C. Gordon, MD Aijaz Ahmed, MD Douglas Dieterich, MD Sammy Saab, MD Rachel Beckerman, PhD

Hepatitis C virus treatment is often restricted in Medicaid patients. This analysis evaluates the clinical and cost impacts of treating all Medicaid patients versus the current status quo.

February 12th 2017

MD Anderson Now an Oncology "Superhub" for Project ECHO

Surabhi Dangi-Garimella, PhD

MD Anderson Cancer Center, which first established its oncology-focused ECHO program in 2014 has now adopted a much bigger role, of a “superhub.”

October 17th 2016

Inconsistent Treatment for Prisoners With Hepatitis C Provokes Lawsuits

Christina Mattina

The rate of inmates infected with the hepatitis C virus is estimated at 17.4% across the United States, and can reach as high as 40% in some states. However, many inmates in state prisons are not permitted to receive the the newest and most expensive treatments for the virus.

October 14th 2016

AJMC in the Press, October 14, 2016

Coverage of our peer-reviewed research in the healthcare and mainstream press.

September 26th 2016

Test Hepatitis C Patients for Hepatitis B Before Treatment, Panel Advises

Christina Mattina

The American Association for the Study of Liver Diseases/Infectious Diseases Society of America Guidance Panel is recommending that before patients begin antiviral therapies for the treatment of hepatitis C, that they be screened for hepatitis B, as well.

September 24th 2016

Clinical Trial Pioneers Transplantation of Hepatitis C-Infected Kidneys

Christina Mattina

An ongoing clinical trial has shown that the use of a recently approved hepatitis C virus (HCV) medication could make it possible to transplant HCV-infected kidneys into non-infected patients.

September 20th 2016

ACLU Sues Colorado Medicaid Over Limits on Hepatitis C Treatment

The dispute between the ACLU and Colorado Medicaid has been seen in other states and with other payers. Policy questions on treatment for hepatitis C virus were examined in a special issue of The American Journal of Managed Care.

September 13th 2016

What We're Reading: Republicans Push for Expanded Exemptions for ACA Penalties

What we're reading, September 13, 2016: GOP bill would exempt people who live in areas with 1 Obamacare plan or none from penalties for not having coverage; hepatitis C drugs threaten to bust prison budgets; and school challenges for children with mental illness.

September 12th 2016

Gilead Again Defends Against Lawsuits Over Patents for Hepatitis C Treatments

The University of Minnesota filed a lawsuit against Gilead Sciences, maintaining that the pharmaceutical company infringed on a patent when it marketed 3 medications for the treatment of the hepatitis C virus.

September 10th 2016

Resistance to HCV Treatment Can Still Be a Challenge

The treatment of chronic hepatitis C virus has been revolutionized by the development of direct-acting antivirals, but a small fraction of patients do experience resistance and treatment failure.

July 3rd 2016

Safety Profile of New Pan-Genomic HCV Drug Similar to Current Treatments

After reviewing the evidence for all approved hepatitis C virus treatments, Advera Health has determined that Gilead Sciences’ newly approved, pan-genomic Epclusa has a similar safety profile as Sovaldi, Harvoni, Daklinza, and Viekira Pak.

June 28th 2016

FDA Approval for Gilead's New Treatment for HCV

Surabhi Dangi-Garimella, PhD

A combination of sofosbuvir and velpatasvir (Epclusa) that is effective against all 6 major forms of the hepatitis C virus (HCV) has received the FDA’s consent to market.

June 16th 2016

Adoption of New Agents and Changes in Treatment Patterns for Hepatitis C: 2010-2014

Xiaoxi Yao, PhD Lindsey R. Sangaralingham, MPH Joseph S. Ross, MD Nilay D. Shah, PhD Jayant A. Talwalkar, MD

New hepatitis C medications have been quickly adopted into practice and increased treatment rate. The median out-of-pocket costs of new medications were relatively low.

June 3rd 2016

AJMC in the Press, June 3, 2016

Recent coverage of our research, in both the healthcare and mainstream press.

May 31st 2016

What We're Reading: Washington Medicaid Program Must Lift HCV Restrictions

What we're reading, May 31, 2016: a federal judge ordered the Washington state Medicaid program to remove restrictions on hepatitis C virus medications; the trouble when drug prices are too low; and the World Health Organization will not consider postponing the Summer Olympics due to the Zika virus.

May 20th 2016

MONDAY: Capitol Hill Event to Highlight New Research Confirming the Need for Improved Access to Hepatitis C Cures

Media Invited to Congressional Briefing Focusing on the Value of Curing Hepatitis C; Feature Remarks by Harvard, Stanford & USC Researchers & NVHR Executive Director

May 17th 2016

Denied Treatment and Real-World Outcomes: Most-Read HCV Stories

Laura Joszt, MA

Over the last year, The American Journal of Managed Care has covered many aspects of the hepatitis C issue: access to treatment, the cost of drugs, exclusivity deals, and more. Here are the most-read articles from the last year.

May 13th 2016

AJMC in the Press, May 13, 2016

Recent coverage of our peer-reviewed research, in the healthcare and mainstream press.

May 13th 2016

5 Things to Know About Hepatitis C Screening and Treatment

As CDC reports a record number of deaths from hepatitis C, it seeks to raise awareness of the need for screening and treatment. Authors and the editor of a special issue of The American Journal of Managed Care will take part in a briefing on the issue.

May 6th 2016

Special Issue of AJMC Examines Policy Questions Surrounding Hepatitis C Treatment

The arrival of direct-acting antivirals to treat hepatitis C virus raised unprecedented policy questions in healthcare. This new drug class was initially met with alarm over cost and barriers to the cure, despite the potential for long-term savings, and represents one of a number of topics explored in a special issue of The American Journal of Managed Care.

<1 2 3 4 5 6 7 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions